Welcome to our dedicated page for Skinhealth Systems SEC filings (Ticker: SKIN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SkinHealth Systems Inc. filings document the regulatory record for a Nasdaq-listed medical aesthetics company formerly known as The Beauty Health Company. The filings identify its Class A common stock, operating and financial results, non-GAAP reconciliations, and material-event disclosures tied to quarterly and annual reporting.
Its SEC record also includes proxy materials for annual stockholder voting, board and committee governance, director appointments, officer departures, compensatory arrangements, capital-structure disclosures and shareholder voting matters. These filings provide the formal disclosure framework for the company behind Hydrafacial, SkinStylus and related professional skin-health offerings.
Beauty Health Co Chief Financial Officer Michael P. Monahan had 26,776 shares of Class A Common Stock withheld by the company to cover tax obligations on vested restricted stock units. The shares were valued at $0.92 per share for this tax-withholding transaction.
After this non-market disposition, which the company states does not represent a sale, Monahan directly holds 1,987,637 shares of Beauty Health Co Class A Common Stock.
Malha Pedro Bruno Ferreira reported acquisition or exercise transactions in this Form 4 filing.
Beauty Health Co reported that President and CEO Pedro Bruno Ferreira Malha received a grant of 2,654,867 restricted stock units (RSUs) of Class A Common Stock as equity compensation. Each RSU represents one share of stock and vests in three equal annual installments starting on the first anniversary of the March 20, 2026 grant date, subject to continued service and certain acceleration rights.
After this award, Malha is shown as beneficially owning 4,845,251 shares of Class A Common Stock directly. The transaction was recorded at a price of $0.00 per share, reflecting that it is a compensation grant rather than an open-market purchase.
MONAHAN MICHAEL P. reported acquisition or exercise transactions in this Form 4 filing.
Beauty Health Co reported that Chief Financial Officer Michael P. Monahan received a grant of 746,681 restricted stock units of Class A Common Stock. These RSUs vest in three equal annual installments starting on March 20, 2026, contingent on continued service and certain acceleration provisions. Following this award, Monahan directly holds 2,014,413 shares or share-equivalent units, reflecting a compensation-related equity grant rather than an open-market transaction.
Menezes Ronald reported acquisition or exercise transactions in this Form 4 filing.
Beauty Health Co reported that Chief Revenue Officer Ronald Menezes received a large equity grant in the form of restricted stock units (RSUs). He was awarded 746,681 RSUs of Class A Common Stock at no purchase price as part of his compensation.
Each RSU represents a future right to receive one share of Class A Common Stock, subject to time-based vesting. The award vests in three equal installments on each of the first three anniversaries of the March 20, 2026 grant date, contingent on continued service and certain acceleration rights. Following this grant, Menezes directly owns 1,759,915 shares of the company’s Class A Common Stock.
Beauty Health Co reported that CSO and COO Sheri Lewis received an equity compensation grant of 746,681 restricted stock units (RSUs) of Class A Common Stock. Each RSU represents a contingent right to receive one share, subject to time-based vesting and continued service conditions.
The RSUs vest in three equal installments on each of the first three anniversaries of the March 20, 2026 grant date, with certain acceleration rights. Following this grant, Lewis beneficially owns 1,609,524 shares of Class A Common Stock directly, reflecting a large, compensation-related, non-market acquisition rather than an open-market purchase.
Beauty Health Co executive Sheri Lewis reported a routine tax-related share disposition. On March 17, she had 51,883 shares of Class A common stock withheld by the company at $1.17 per share to cover tax obligations on vesting restricted stock units. The footnote clarifies this was not an open-market sale, and she still directly holds 862,843 shares after the transaction.
Beauty Health Co Chief Revenue Officer reports tax share withholding. Ronald Menezes had 61,471 shares of Class A Common Stock withheld at $1.17 per share on March 17, 2026 to cover taxes on vesting restricted stock units. After this non-sale disposition, he directly holds 1,013,234 shares.
Beauty Health Co Chief Financial Officer Michael P. Monahan reported a tax-related share disposition tied to vesting of restricted stock units. The filing shows 58,573 shares of Class A Common Stock valued at $1.17 per share were withheld by the company to satisfy tax withholding requirements and explicitly notes this does not represent a sale in the market. After this withholding, Monahan directly holds 1,267,732 shares of Class A Common Stock, indicating he retains a substantial equity position following the RSU vesting event.
The Beauty Health Company files its annual report describing a global medical aesthetics business built around Hydrafacial devices and recurring consumables. The company uses a razor/razor-blade model, selling Delivery Systems and single-use tips, solutions and serums to providers such as dermatologists and medical spas.
About 69% of U.S. and Canadian sales come from the professional medical channel, and approximately 35% of 2025 net sales were generated outside the United States and Canada. Beauty Health reports aided Hydrafacial brand awareness of 38% among U.S. esthetics consumers and estimates roughly 60% U.S. market share in the microdermabrasion category.
The report details a growth strategy focused on salesforce discipline, demand-driving marketing, and clinically supported innovation, including SkinStylus microneedling and a potential HydraScalp relaunch. It also highlights extensive risk factors, patent protection with 226 granted patents and 84 pending applications, moderate seasonality with stronger fourth-quarter results, and heavy U.S. and international regulatory oversight of its devices and cosmetic products.
The Beauty Health Company reported mixed 2025 results, with lower sales but much stronger profitability. Net sales were $300.8M, down 10.0% from 2024, as delivery system sales fell even though consumables held up.
Gross margin improved sharply to 65.3% from 54.5%, helped by fewer inventory charges and a richer mix of consumables. Net loss narrowed to $9.5M from $29.1M, and adjusted EBITDA increased to $45.1M from $12.3M, reflecting lower operating expenses and better margins. Cash, cash equivalents, and restricted cash were $232.7M at December 31, 2025, while convertible senior notes declined to $364.4M in total. For 2026, the company guides net sales of $285–$305M and adjusted EBITDA of $35–$45M, implying relatively stable revenue with continued focus on profitability.